Calcipotriol is a synthetic vitamin D₃ analogue developed for the treatment of psoriasis. It was introduced in the late 1980s to provide the therapeutic benefits of vitamin D while minimizing calcium-related side effects. Research focused on modifying the vitamin D structure to selectively regulate skin cell growth and differentiation. Calcipotriol was found to effectively reduce excessive keratinocyte proliferation seen in psoriatic lesions. Its topical use showed good efficacy with a favorable safety profile. The drug was first approved in Europe and later worldwide. It became widely used as monotherapy or in combination with corticosteroids. Calcipotriol was subsequently included in major pharmacopeias for quality control. Standardized formulations improved consistency and patient compliance. Today, calcipotriol remains a cornerstone in topical psoriasis management.
